TTY Biopharm Co Ltd (4105) — Cash Flow-to-Debt Ratio
TTY Biopharm Co Ltd (4105) has a Cash Flow-to-Debt Ratio of 0.24x as of December 2025, meaning its operating cash flow of NT$778.89 Million could theoretically repay 0% of its total liabilities (NT$3.30 Billion) in one year. See TTY Biopharm Co Ltd (4105) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
TTY Biopharm Co Ltd Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for TTY Biopharm Co Ltd across 9 annual periods. Also explore TTY Biopharm Co Ltd (4105) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for TTY Biopharm Co Ltd (2017–2025)
Year-by-year debt coverage analysis for TTY Biopharm Co Ltd. For market capitalisation and broader financial context, see 4105 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.53x | NT$1.76 Billion | NT$3.30 Billion | ▲ +32.7% |
| 2024 | 0.40x | NT$1.35 Billion | NT$3.35 Billion | ▲ +25.0% |
| 2023 | 0.32x | NT$1.09 Billion | NT$3.37 Billion | ▼ -12.2% |
| 2022 | 0.37x | NT$1.24 Billion | NT$3.37 Billion | ▲ +3.1% |
| 2021 | 0.36x | NT$1.26 Billion | NT$3.53 Billion | ▲ +122.0% |
| 2020 | 0.16x | NT$526.35 Million | NT$3.28 Billion | ▼ -55.2% |
| 2019 | 0.36x | NT$1.21 Billion | NT$3.38 Billion | ▼ -11.4% |
| 2018 | 0.40x | NT$1.07 Billion | NT$2.66 Billion | ▲ +37.5% |
| 2017 | 0.29x | NT$996.52 Million | NT$3.40 Billion | — |